NCT07549100 Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
| NCT ID | NCT07549100 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shandong Provincial Hospital |
| Condition | Locally Advanced Esophageal Squamous Cell Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-05-15 |
| Primary Completion | 2027-12-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a single-arm, single-center, open-label, observational clinical study. A total of 30 patients with initially unresectable locally advanced esophageal squamous cell carcinoma will be enrolled.Eligible patients will receive albumin-bound paclitaxel (260 mg/m², day 1, every 3 weeks \[Q3W\]) plus cisplatin (75 mg/m²) or carboplatin (AUC = 5), in combination with tislelizumab (200 mg, day 2, Q3W), for 2-4 cycles. Tumor staging will be reassessed thereafter, and the feasibility of surgical resection will be determined based on multidisciplinary team (MDT) discussion.The primary endpoint is the conversion rate to surgery. Secondary endpoints include pathological complete response (pCR), objective response rate (ORR), and safety.
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent is obtained prior to any study-related procedures. 2. Age 18 to 75 years, inclusive; both male and female patients are eligible. 3. Histologically and radiologically confirmed thoracic esophageal squamous cell carcinoma (ESCC) with initially unresectable locally advanced disease, defined as: T4b tumors invading adjacent critical structures, including the heart, great vessels, trachea, or other adjacent organs (including liver, pancreas, lung, or spleen); or Multiple-station or bulky lymph node metastases. 4. No evidence of distant metastasis. 5. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 7. Estimated life expectancy of ≥6 months. 8. Adequate organ function, as defined below (without transfusion of blood products or use of hematopoietic growth factors within 14 days prior to assessment): Hematologic fu